Non-radiographic Axial Spondyloarthritis (Nr-AxSpA) Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | UCB Biopharma, Novartis, Jiangsu HengRui

Posted on
by

Non-radiographic Axial Spondyloarthritis (Nr-AxSpA) Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | UCB Biopharma, Novartis, Jiangsu HengRui
DelveInsight’s “Non-radiographic Axial Spondyloarthritis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Non-radiographic Axial Spondyloarthritis, historical and forecasted epidemiology as well as the Non-radiographic Axial Spondyloarthritis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

DelveInsight’s “Non-radiographic Axial Spondyloarthritis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Non-radiographic Axial Spondyloarthritis, historical and forecasted epidemiology as well as the Non-radiographic Axial Spondyloarthritis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Non-radiographic Axial Spondyloarthritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Non-radiographic Axial Spondyloarthritis Market Forecast

 

Some of the key facts of the Non-radiographic Axial Spondyloarthritis Market Report: 

  • The Non-radiographic Axial Spondyloarthritis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • There were approximately 1,708,000 prevalent cases of Nr-AxSpA in the 7MM population in 2022. During the predicted period (from 2023 to 2022) it is expected that these cases would rise
  • In the 7MM, there were 864,000 diagnosed cases of Nr-AxSpA in total in 2022. During the predicted period (2023–2022), an increase in these cases is anticipated
  • HLA-B27 accounted for 74% of Nr-AxSpA cases in Germany according to gene-specific diagnostic prevalence, while ERAP 1, IL12, IL-17, and IL-23 accounted for 26% of cases in 2022
  • France has the fewest diagnosed prevalent cases of Nr-AxSpA overall among the EU4 nations, with only 54,000 cases in 2022
  • There were 900 diagnosed prevalent cases of Nr-AxSpA in Japan in 2022. By 2032, more of these incidents are expected to occur
  • Key Non-radiographic Axial Spondyloarthritis Companies: UCB Biopharma, Novartis, Jiangsu HengRui Medicine Co., Ltd., Eli Lilly and Company, Amgen, Sun Pharma, and others
  • Key Non-radiographic Axial Spondyloarthritis Therapies: Bimekizumab, Secukinumab, SHR0302, Ixekizumab, Brodalumab 210 mg, SUNPG1622 I dose, and others
  • The Non-radiographic Axial Spondyloarthritis epidemiology based on gender analyzed that the prevalent population of Nr-AxSpA showed a female predominance
  • The Non-radiographic Axial Spondyloarthritis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Non-radiographic Axial Spondyloarthritis pipeline products will significantly revolutionize the Non-radiographic Axial Spondyloarthritis market dynamics.

 

Non-radiographic Axial Spondyloarthritis Overview

Axial non-radiographic The axial spondyloarthritis (axSpA) family of inflammatory diseases includes spondyloarthritis (Nr-AxSpA). Although the spine and SI joints are affected by these disorders, other regions of the body may also show signs and symptoms.

 

Get a Free sample for the Non-radiographic Axial Spondyloarthritis Market Report 

https://www.delveinsight.com/report-store/non-radiographic-axial-spondyloarthritis-nr-axspa-market

 

Non-radiographic Axial Spondyloarthritis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Non-radiographic Axial Spondyloarthritis Epidemiology Segmentation:

The Non-radiographic Axial Spondyloarthritis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Non-radiographic Axial Spondyloarthritis
  • Prevalent Cases of Non-radiographic Axial Spondyloarthritis by severity
  • Gender-specific Prevalence of Non-radiographic Axial Spondyloarthritis
  • Diagnosed Cases of Episodic and Chronic Non-radiographic Axial Spondyloarthritis

 

Download the report to understand which factors are driving Non-radiographic Axial Spondyloarthritis epidemiology trends @ Non-radiographic Axial Spondyloarthritis Epidemiology Forecast

 

Non-radiographic Axial Spondyloarthritis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Non-radiographic Axial Spondyloarthritis market or expected to get launched during the study period. The analysis covers Non-radiographic Axial Spondyloarthritis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Non-radiographic Axial Spondyloarthritis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Non-radiographic Axial Spondyloarthritis Therapies and Key Companies

  • Bimekizumab: UCB Biopharma
  • Secukinumab: Novartis
  • SHR0302: Jiangsu HengRui Medicine Co., Ltd.
  • Ixekizumab: Eli Lilly and Company
  • Brodalumab 210 mg: Amgen
  • SUNPG1622 I dose: Sun Pharma

 

Discover more about therapies set to grab major Non-radiographic Axial Spondyloarthritis market share @ Non-radiographic Axial Spondyloarthritis Treatment Market 

 

Scope of the Non-radiographic Axial Spondyloarthritis Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Non-radiographic Axial Spondyloarthritis Companies: UCB Biopharma, Novartis, Jiangsu HengRui Medicine Co., Ltd., Eli Lilly and Company, Amgen, Sun Pharma, and others
  • Key Non-radiographic Axial Spondyloarthritis Therapies: Bimekizumab, Secukinumab, SHR0302, Ixekizumab, Brodalumab 210 mg, SUNPG1622 I dose, and others
  • Non-radiographic Axial Spondyloarthritis Therapeutic Assessment: Non-radiographic Axial Spondyloarthritis current marketed and Non-radiographic Axial Spondyloarthritis emerging therapies
  • Non-radiographic Axial Spondyloarthritis Market Dynamics: Non-radiographic Axial Spondyloarthritis market drivers and Non-radiographic Axial Spondyloarthritis market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Non-radiographic Axial Spondyloarthritis Unmet Needs, KOL’s views, Analyst’s views, Non-radiographic Axial Spondyloarthritis Market Access and Reimbursement 

 

To know more about Non-radiographic Axial Spondyloarthritis companies working in the treatment market, visit @ Non-radiographic Axial Spondyloarthritis Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Non-radiographic Axial Spondyloarthritis Market Report Introduction

2. Executive Summary for Non-radiographic Axial Spondyloarthritis

3. SWOT analysis of Non-radiographic Axial Spondyloarthritis

4. Non-radiographic Axial Spondyloarthritis Patient Share (%) Overview at a Glance

5. Non-radiographic Axial Spondyloarthritis Market Overview at a Glance

6. Non-radiographic Axial Spondyloarthritis Disease Background and Overview

7. Non-radiographic Axial Spondyloarthritis Epidemiology and Patient Population

8. Country-Specific Patient Population of Non-radiographic Axial Spondyloarthritis 

9. Non-radiographic Axial Spondyloarthritis Current Treatment and Medical Practices

10. Non-radiographic Axial Spondyloarthritis Unmet Needs

11. Non-radiographic Axial Spondyloarthritis Emerging Therapies

12. Non-radiographic Axial Spondyloarthritis Market Outlook

13. Country-Wise Non-radiographic Axial Spondyloarthritis Market Analysis (2019–2032)

14. Non-radiographic Axial Spondyloarthritis Market Access and Reimbursement of Therapies

15. Non-radiographic Axial Spondyloarthritis Market Drivers

16. Non-radiographic Axial Spondyloarthritis Market Barriers

17.  Non-radiographic Axial Spondyloarthritis Appendix

18. Non-radiographic Axial Spondyloarthritis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services